Most of oral targeted therapies are tyrosine kinase inhibitors (TKIs). Oral administration
generates a complex step in the pharmacokinetics (PK) of these drugs. Inter-individual PK …

Aims Oral therapies, including hormone‐based or targeted therapies, have recently taken an
increasing place in cancer treatment. In this context, a state of the art of the available studies …

Many studies have demonstrated that non-adherence to oral anticancer drugs (OACDs) has
challenged treatment efficacy. Otherwise, few validated tools exist to measure patients' …

Background In the last decade, the use of imatinib has brought a paradigm shift in the
management of chronic myeloid leukemia (CML). In India, imatinib has been available for …

BACKGROUND: Various factors, including patient demographic and socioeconomic
characteristics, patient out-of-pocket (OOP) costs, therapy-related factors, clinical …

BACKGROUND Tyrosine kinase inhibitors (TKIs) improve the survival of patients with
chronic myeloid leukemia (CML) dramatically; however, nonadherence to TKI therapy may …

Introduction: The main goal of treatment in cancer patients is to achieve the highest
therapeutic effectiveness with the least iatrogenic toxicity. Tyrosine kinase inhibitors (TKIs) …

Purpose To evaluate chronic myeloid leukemia (CML) patients' adherence to peroral
tyrosine kinase inhibitors in Finland and to compare this with adherence as estimated by …

Purpose To investigate the experiences of adults living with chronic myeloid leukaemia and
treated with tyrosine kinase inhibitors, with particular reference to factors influencing …

Objectives To obtain insight into patients' reasons for medication (non) adherence in chronic
myeloid leukaemia (CML) and needs and wishes regarding information and communication …